Mediantechn

Median Technologies has announced the formation of a Strategic Review Committee to evaluate a range of strategic alternatives, including a potential separation of its iCRO business, a potential U.S. listing, and other options, aiming to unlock intrinsic value and accelerate its eyonis pan-cancer strategy. The company also established a dedicated R&D Committee to oversee its scientific roadmap. The move follows recent milestones such as FDA clearance and CE marking for eyonis LCS, a distribution partnership with Tempus AI, and a 50 million euro capital raise. Median's board believes its current valuation does not reflect the growth potential of its eyonis and iCRO businesses, which have a record order backlog of 82.4 million euros as of June 30, 2026. No decision has been made yet, and the committee will engage independent advisors to support its work.